Rosemont Pharms
1 products tracked · names used in filings: Rosemont Pharms
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 16 Oct 2026🇺🇸 FDA approval
FDA approves Yulzety (rivaroxaban): new dosage form
Rosemont Pharms; NDA221033; New dosage form; suspension · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Yulzety rivaroxaban | Approved | 2026-10-16 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.